Drugs / Anti-GPC3-IRDye800CW
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05047510 | Sep 2021 → Dec 2025 overdue | hepatocellular carcinoma | Chinese Academy of Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-GPC3-IRDye800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047510 ↗ |
| Target | GPC3 | “intraoperative fluorescence imaging targeting GPC3” NCT05047510 ↗ |